219 related articles for article (PubMed ID: 15848608)
1. Influence of angiotensin-converting enzyme polymorphism gene, IGF-1, and other factors in the response rate of hematocrit to enalapril treatment in patients with posttransplant erythrocytosis.
Jimeno L; Rodado R; Barrios Y; Campos M; Llorente S; Nicolas F; Minguela A
Transplant Proc; 2005 Mar; 37(2):1012-3. PubMed ID: 15848608
[TBL] [Abstract][Full Text] [Related]
2. Ramipril in post-renal transplant erythrocytosis.
Esposito R; Giammarino A; De Blasio A; Martinelli V; Cirillo F; Scopacasa F; Federico S; Russo D
J Nephrol; 2007; 20(1):57-62. PubMed ID: 17347974
[TBL] [Abstract][Full Text] [Related]
3. Effects of losartan or enalapril on hemoglobin, circulating erythropoietin, and insulin-like growth factor-1 in patients with and without posttransplant erythrocytosis.
Wang AY; Yu AW; Lam CW; Yu LM; Li PK; Goh J; Lui SF
Am J Kidney Dis; 2002 Mar; 39(3):600-8. PubMed ID: 11877580
[TBL] [Abstract][Full Text] [Related]
4. Effect of the angiotensin-converting enzyme inhibitor enalapril on post-transplant erythrocytosis.
Marubayashi S; Yamamoto H; Shibata S; Fudaba Y; Miyata Y; Fukuma K; Okada K; Hinoi T; Ikeda M; Maeda T; Oshiro Y; Dohi K
Hiroshima J Med Sci; 1998 Sep; 47(3):121-4. PubMed ID: 9810784
[TBL] [Abstract][Full Text] [Related]
5. Influence of angiotensin I-converting enzyme polymorphism on development of post-transplant erythrocytosis in renal graft recipients.
Kedzierska K; Kabat-Koperska J; Safranow K; Domański M; Gołembiewska E; Bober J; Bohatyrewicz R; Ciechanowski K
Clin Transplant; 2008; 22(2):156-61. PubMed ID: 18339134
[TBL] [Abstract][Full Text] [Related]
6. Iron deficiency--an underrecognized problem in nonanemic and erythrocytic kidney transplant recipients: risks and effects of ACEI and of iron treatment.
Jimeno L; Rodado R; Campos M; Lanuza M
Transplant Proc; 2005 Mar; 37(2):1007-8. PubMed ID: 15848606
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of enalapril and theophylline on polycythemia after renal transplantation.
Ok E; Akçiçek F; Töz H; Kürşat S; Töbü M; Başçi A; Mees EJ
Transplantation; 1995 Jun; 59(11):1623-6. PubMed ID: 7778179
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin converting enzyme gene polymorphism and development of post-transplant erythrocytosis.
Yildiz A; Yazici H; Cine N; Kazancioglu R; Akkaya V; Sever MS; Ark E; Erginel-Unaltuna N
J Nephrol; 2003; 16(3):399-403. PubMed ID: 12832741
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibition induces apoptosis in erythroid precursors and affects insulin-like growth factor-1 in posttransplantation erythrocytosis.
Glicklich D; Burris L; Urban A; Tellis V; Greenstein S; Schechner R; Devarajan P; Croizat H
J Am Soc Nephrol; 2001 Sep; 12(9):1958-1964. PubMed ID: 11518790
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-converting enzyme inhibition in the treatment of renal transplant erythrocytosis. Clinical experience and observation of mechanism.
Danovitch GM; Jamgotchian NJ; Eggena PH; Paul W; Barrett JD; Wilkinson A; Lee DB
Transplantation; 1995 Jul; 60(2):132-7. PubMed ID: 7624954
[TBL] [Abstract][Full Text] [Related]
11. Impact of angiotensin-converting enzyme gene polymorphism on neurohormonal responses to high- versus low-dose enalapril in advanced heart failure.
Tang WH; Vagelos RH; Yee YG; Fowler MB
Am Heart J; 2004 Nov; 148(5):889-94. PubMed ID: 15523323
[TBL] [Abstract][Full Text] [Related]
12. Long-term therapy for postrenal transplant erythrocytosis with ACE inhibitors: efficacy, safety and action mechanisms.
Montanaro D; Groupuzzo M; Boscutti G; Risaliti A; Bresadola F; Mioni G
Clin Nephrol; 2000 Apr; 53(4):suppl 47-51. PubMed ID: 10809436
[TBL] [Abstract][Full Text] [Related]
13. Effect of angiotensin converting enzyme inhibitors on 1.25-(OH)2 D levels of hypertensive patients. Relationship with ACE polymorphisms.
Pérez-Castrillón JL; Justo I; Sanz A; De Luis D; Dueñas A
Horm Metab Res; 2006 Dec; 38(12):812-6. PubMed ID: 17163356
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin, interleukin-3, interleukin-11, and GM-CSF in posttransplant erythrocytosis treated with enalapril.
Hu RH; Lee PH; Lee CJ
Transplant Proc; 1996 Jun; 28(3):1545-7. PubMed ID: 8658779
[No Abstract] [Full Text] [Related]
15. Role of ACE inhibitors in the treatment of erythrocytosis in patients with renal allograft.
Pisani F; Tisone G; Alciati E; Vennarecci G; Pieragostini E; Casciani CU
Transplant Proc; 1994 Oct; 26(5):2602-3. PubMed ID: 7940809
[No Abstract] [Full Text] [Related]
16. Effects of erythropoietin, angiotensin II, and angiotensin-converting enzyme inhibitor on erythroid precursors in patients with posttransplantation erythrocytosis.
Glicklich D; Kapoian T; Mian H; Gilman J; Tellis V; Croizat H
Transplantation; 1999 Jul; 68(1):62-6. PubMed ID: 10428268
[TBL] [Abstract][Full Text] [Related]
17. Correction of posttransplant erythrocytosis with enalapril.
Rell K; Koziak K; Jarzyo I; Lao M; Gaciong Z
Transplantation; 1994 Apr; 57(7):1059-63. PubMed ID: 8165703
[TBL] [Abstract][Full Text] [Related]
18. The role of ace gene polymorphism in the development of angioedema secondary to angiotensin converting enzyme inhibitors and angiotensin II receptor blockers.
Gulec M; Caliskaner Z; Tunca Y; Ozturk S; Bozoglu E; Gul D; Erel F; Kartal O; Karaayvaz M
Allergol Immunopathol (Madr); 2008; 36(3):134-40. PubMed ID: 18680700
[TBL] [Abstract][Full Text] [Related]
19. Enalapril and losartan affect lipid peroxidation in renal transplant recipients with renin-angiotensin system polymorphisms.
Rashtchizadeh N; Aghaeishahsavari M; Argani H; Noroozianavval M; Veisi P; Ghorbanihaghjo A
Clin Biochem; 2007 Feb; 40(3-4):194-200. PubMed ID: 17222813
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
